To further investigate RUNX3-mediated cetuximab-dependent cell death in NSCLC cells, we examined whether RUNX3 re-expression (activation) was beneficial in treatments with 47Sc-DTPA-cetuximab. Here, RUNX3 is linked to non-small cell lung carcinoma.